Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Developing effective vaccines against SARS-CoV-2 that consider manufacturing limitations, equitable access, and acceptance is necessary for developing platforms to produce antigens that can be efficiently pres...

Source: Microbial Cell Factories - February 6, 2024 Category: Microbiology Authors: Norma A. Valdez ‑Cruz, Diego Rosiles-Becerril, Constanza E. Martínez-Olivares, Enrique García‑Hernández, Laura Cobos-Marín, Daniel Garzón, Francisco E. López-Salas, Guadalupe Zavala, Axel Luviano, Alejandro Olvera, Alejandro Alagón, Octavio T. Tags: Research Source Type: research